- Home
- ALVR vs ONCY Comparison
ALVR vs ONCY Comparison
Compare ALVR & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVR
- ONCY
- Stock Information
- Founded
- ALVR 2013
- ONCY 1998
- Country
- ALVR United States
- ONCY Canada
- Employees
- ALVR N/A
- ONCY N/A
- Industry
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- ONCY Pharmaceuticals and Biotechnology
- Sector
- ALVR Health Care
- ONCY Health Care
- Exchange
- ALVR Nasdaq
- ONCY Nasdaq
- Market Cap
- ALVR 48.8M
- ONCY 56.2M
- IPO Year
- ALVR 2020
- ONCY 1999
- Fundamental
- Price
- ALVR $9.63
- ONCY $0.73
- Analyst Decision
- ALVR
- ONCY Strong Buy
- Analyst Count
- ALVR 0
- ONCY 2
- Target Price
- ALVR N/A
- ONCY $4.00
- AVG Volume (30 Days)
- ALVR 22.4K
- ONCY 564.7K
- Earning Date
- ALVR 03-14-2025
- ONCY 03-06-2025
- Dividend Yield
- ALVR N/A
- ONCY N/A
- EPS Growth
- ALVR N/A
- ONCY N/A
- EPS
- ALVR N/A
- ONCY N/A
- Revenue
- ALVR N/A
- ONCY N/A
- Revenue This Year
- ALVR N/A
- ONCY N/A
- Revenue Next Year
- ALVR N/A
- ONCY N/A
- P/E Ratio
- ALVR N/A
- ONCY N/A
- Revenue Growth
- ALVR N/A
- ONCY N/A
- 52 Week Low
- ALVR $7.96
- ONCY $0.67
- 52 Week High
- ALVR $24.15
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- ALVR 45.63
- ONCY 40.10
- Support Level
- ALVR $9.55
- ONCY $0.71
- Resistance Level
- ALVR $10.41
- ONCY $0.79
- Average True Range (ATR)
- ALVR 0.44
- ONCY 0.04
- MACD
- ALVR 0.05
- ONCY 0.00
- Stochastic Oscillator
- ALVR 22.77
- ONCY 32.71
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.